Addressing the questions of tomorrow: melphalan and new combinations as conditioning regimens before autologous hematopoietic progenitor cell transplantation in multiple myeloma

Bibliography

• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. Cancer J Clin 2012;62:10-29
   PubMed Web of Science ®Google Scholar
• Durie BG, Salmon S. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975;36:842-54
   PubMed Web of Science ®Google Scholar
• Richardson PG, Sonneveld P, Schuster MW, Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352:2487-98
   PubMed Web of Science ®Google Scholar
• Knight R. IMiDs: a novel class of immunomodulators. Semin Oncol 2005;32:S24-30
   PubMed Web of Science ®Google Scholar
• Richardson PG, Weller E, Lonial S, Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 2010;116:679-86
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Hayman SR, Lacy MQ, Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 2005;106:4050-3
   PubMed Web of Science ®Google Scholar
• Laubach JP, Mitsiades CS, Mahindra A, Novel therapies in the treatment of multiple myeloma. J Natl Compr Canc Netw 2009;7:947-60
   PubMed Web of Science ®Google Scholar
• Jagannath S, Kyle RA, Palumbo A, The current status and future of multiple myeloma in the clinic. Clin Lymphoma Myeloma Leuk 2010;10:28-43
   PubMed Web of Science ®Google Scholar
• Attal M, Harousseau JL, Stoppa AM, A prospective randomized trial of Autologous Bone Marrow Transplantation and chemotherapy in Multiple Myeloma. N Engl J Med 1996;335:91-7
   PubMed Web of Science ®Google Scholar
• Fermand JP, Ravaud P, Chevret S, High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood 1998;92:3131-6
   PubMed Web of Science ®Google Scholar
• Child JA, Morgan GJ, Davies FE, High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003;348:1875-83
   PubMed Web of Science ®Google Scholar
• Bladé J, Rosinol L, Sureda A, High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood 2005;106:3755-9
   PubMed Web of Science ®Google Scholar
• Fermand JP, Katsahian S, Divine M, High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol 2005;23:9227-33
   PubMed Web of Science ®Google Scholar
• Barlogie B, Kyle RA, Anderson KC, Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol 2006;24:929-36
   PubMed Web of Science ®Google Scholar
• Giralt S. Stem cell transplantation for multiple myeloma: current and future status. Hematology 2012;17(Suppl 1):S117-20
   PubMedGoogle Scholar
• Harousseau JL, Attal M, Avet-Loiseau H. The role of complete response in multiple myeloma. Blood 2009;114:3139-46
   PubMed Web of Science ®Google Scholar
• Chanan-Kahn A, Giralt S. Importance of achieving a complete response in multiple myeloma, and the impact of novel agents. J Clin Oncol 2010;28:2612-24
   PubMed Web of Science ®Google Scholar
• Harousseau JL, Moreau P. Autologous hematopoietic stem cell transplantation for multiple myeloma. N Engl J Med 2009;360:2645-54
   PubMed Web of Science ®Google Scholar
• Stewart AK, Richardson PG, San-Miguel JF. How I treat multiple myeloma in younger patients. Blood 2009;114:5436-43
   PubMed Web of Science ®Google Scholar
• Ladetto M, Pagliano G, Ferrero S, Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografter myeloma. J Clin Oncol 2010;28:2077-84
   PubMed Web of Science ®Google Scholar
• Mellqvist UH, Westin J, Gimsing P, Improved response rate with bortezomib consolidation after high-dose melphalan: first results of a nordic myeloma study group randomized phase III trial. Blood 2009;114:530a
   Google Scholar
• Attal M, Lauwers-Cances V, Marit G, Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. NEJM 2012;366:1782-91
   PubMed Web of Science ®Google Scholar
• Ludwig H, Durie BG McCarthy P, IMWG consensus on maintenance therapy in multiple myeloma. Blood 2012;119:3003-15
   PubMed Web of Science ®Google Scholar
• McCarthy PL, Owzar K, Hofmeister CC, Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med 2012;366:1770-81
   PubMed Web of Science ®Google Scholar
• Moreau P, Attal M, Harousseau JL. New developments in conditioning regimens before auto-SCT in multiple myeloma. Bone Marrow Transplant 2011;46(7):911-15
   PubMed Web of Science ®Google Scholar
• Kumar S, Fonseca R, Ketterling RP, Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics. Blood 2012;119(9):2100-5
   PubMed Web of Science ®Google Scholar
• Munshi NC, Anderson KC, Bergsagel PL, Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood 2011;117(18):4696-700
   PubMed Web of Science ®Google Scholar
• Kumar SK, Mikhael JR, Buadi FK, Management of newly diagnosed symptomatic multiple myeloma: updated Mayo stratification of myeloma and risk-adapted therapy (mSMART) consensus guidelines. Mayo Clin Proc 2009;84(12):1095-110
   PubMed Web of Science ®Google Scholar
• Rajkumar SV. Treatment of multiple myeloma. Nat Rev Clin Oncol 2011;8:479-91
   PubMed Web of Science ®Google Scholar
• Krishnan A. American Society Clinical Oncology Annual Meeting. Educational Book 2012. p. 502-7
   Google Scholar
• Gertz MA, Ansell SM, Dingli D, Autologous stem cell transplant in 716 patients with multiple myeloma: low treatment related mortality, feasibility of outpatient transplant, and effect of a multidisciplinary quality initiative. Mayo Clin Proc 2008;83(10):1131-8
   PubMed Web of Science ®Google Scholar
• Rajkumar SV. Doublets, triplets, or quadruplets of novel agents in newly diagnosed myeloma? Hematol Am Soc Hematol Educ Program 2012;2012:354-61
   PubMedGoogle Scholar
• Cavo M, Tacchetti P, Patriarca F, Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before and consolidation therapy after double autologous stem cell transplantation in newly diagnosed multiple myeloma. A randomized phase 3 study. Lancet 2010;376:2075-85
   PubMed Web of Science ®Google Scholar
• Hahn T, Wingard J, Anderson K, The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of multiple myeloma: an evidence-based review. Biol Blood Marrow Transplant 2003;9:4-37
   PubMed Web of Science ®Google Scholar
• Barosi G, Boccadoro M, Cavo M, Management of multiple myeloma and related-disorders: guidelines from the Italian Society of Hematology (SIE), Italian Society of Experimental Hematology (SIES) and Italian Group for Bone Marrow Transplantation (GITMO). Haematologica 2004;89(6):717-41
   PubMed Web of Science ®Google Scholar
• Smith A, Wisloff F, Samson D. Guidelines on the diagnosis and management of multiple myeloma 2005. Br J Haematol 2006;132(4):410-51. 23-25
   PubMed Web of Science ®Google Scholar
• Koreth J, Cutler CS, Djulbegovic B, High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials. Biol Blood Marrow Transplant 2007;13(2):183-96
   PubMed Web of Science ®Google Scholar
• Barlogie B, Jagannath S, Vesole DH, Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 1997;89:789-93
   PubMed Web of Science ®Google Scholar
• Attal M, Harousseau JL, Facon T, Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003;349(26):2495-502
   PubMed Web of Science ®Google Scholar
• Harousseau JL. Hematopoietic stem cell transplantation in multiple myeloma. J Natl Compr Canc Netw 2009;7:961-70
   PubMed Web of Science ®Google Scholar
• Cavo M, Tosi P, Zamagni E, Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: bologna 96 clinical study. J Clin Oncol 2007;25(17):2434-41
   PubMed Web of Science ®Google Scholar
• Naumann-Winter F, Greb A, Borchmann P, First-line tandem high-dose chemotherapy and autologous stem cell transplantation versus single high-dose chemotherapy and autologous stem cell transplantation in multiple myeloma, a systematic review of controlled studies. Cochrane Database Syst Rev 2012;10:CD004626
   PubMedGoogle Scholar
• Patriarca F, Petrucci MT, Bringhen S, Considerations in the treatment of multiple myeloma: a consensus statement from Italian experts. Eur J Haematol 2009;82:93-105
   PubMed Web of Science ®Google Scholar
• Palumbo A, Rajkumar SV. Multiple myeloma: chemotherapy or transplantation in the era of new drugs. Eur J Haematol 2010;84:379-90
   PubMed Web of Science ®Google Scholar
• Blade' J, Rosinol L, Cibeira MT, Hematopoietic stem cell transplantation for multiple myeloma beyond 2010. Blood 2010;115:3655-63
   PubMed Web of Science ®Google Scholar
• Bensinger W. Stem-cell transplantation for multiple myeloma in the era of novel drugs. J Clin Oncol 2008;26(3):480-92
   PubMed Web of Science ®Google Scholar
• Lonial S, Cavenagh J. Emerging combination treatment strategies containing novel agents in newlydiagnosed multiple myeloma. Br J Haematol 2009;145(6):681-708
   PubMed Web of Science ®Google Scholar
• Cavo M, Rajkumar SV, Palumbo A, International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood 2011;117(23):6063-73
   PubMed Web of Science ®Google Scholar
• Passweg JR, Baldomero H, Gratwohl A, The EBMT activity survey: 1990-2010. Bone Marrow Transplant 2012;47(7):906-23
   PubMed Web of Science ®Google Scholar
• Reece DE, Bredeson C, Perez WS, Autologous stem cell transplantation in multiple myeloma patients < 60 vs > 60 years of age. Bone Marrow Transplant 2003;32(12):1135-43
   PubMed Web of Science ®Google Scholar
• Bergel F, Stock JA. Cytotoxic alpha amino acids and endopeptidase. Br Emp Cancer Comp Annu 1953;31:6-21
   Google Scholar
• Sarosy G, Leyland-Jones B, Soochan P, Cheson BD. The systemic administration of intravenous melphalan. J Clin Oncol 1988;6:1768-82
   PubMed Web of Science ®Google Scholar
• Bayraktar UD, Bashir Q, Qazilbash M, Fifty years of melphalan use in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2013;19(3):344-56
   PubMed Web of Science ®Google Scholar
• Singhal S, Powles R, Treleaven J, Melphalan alone prior to allogeneic bone marrow transplantation from HLA-identical sibling donors for hematologic malignancies: alloengraftment with potential preservation of fertility in women. Bone Marrow Transplant 1996;18:1049-55
   PubMed Web of Science ®Google Scholar
• Hersh MR, Ludden TM, Kuhn JG, Knight WA III. Pharmacokinetics of high dose melphalan. Invest New Drugs 1983;1:331-4
   PubMedGoogle Scholar
• Samuels BL, Bitran JD. High-dose intravenous melphalan: a review. J Clin Oncol 1995;13:1786-99
   PubMed Web of Science ®Google Scholar
• Lazarus HM, Herzig RH, Graham-Pole J, Intensive melphalan chemotherapy and cryopreserved autologous bone marrow transplantation for the treatment of refractory cancer. J Clin Oncol 1983;1:359-67
   PubMed Web of Science ®Google Scholar
• Kouvaris JR, Kouloulias VE, Vlahos LJ. Amifostine: the first selective-target and broad-spectrum radioprotector. Oncologist 2007;12:738-47
   PubMed Web of Science ®Google Scholar
• Amifostine: BC Cancer Agency. British Columbia Cancer Agency. 2006. Available from: http://www.bccancer.bc.ca/HPI/DrugDatabase/DrugIndexPro/amifostine.htm
   Google Scholar
• Capelli D, Santini G, De Souza C, Amifostine can reduce mucosal damage after high-dose melphalan conditioning for peripheral blood progenitor cell autotransplant: a retrospective study. Br J Haematol 2000;110(2):300-7
   PubMed Web of Science ®Google Scholar
• Phillips GL II, Bernstein SH, Liesveld JL, A phase I trial: dose escalation of melphalan in the "BEAM" regimen using amifostine cytoprotection. Biol Blood Marrow Transplant 2011;17:1033-42
   PubMed Web of Science ®Google Scholar
• Lilleby K, Garcia P, Gooley T, A prospective, randomized study of cryotherapy during administration of high-dose melphalan to decrease the severity and duration of oral mucositis in patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 2006;37(11):1031-5
   PubMed Web of Science ®Google Scholar
• Worthington HV, Clarkson JE, Bryan G, Interventions for preventing oral mucositis for patients with cancer receiving treatment. Cochrane Database Syst Rev 2011(4):CD000978
   PubMed Web of Science ®Google Scholar
• Selby PJ, McElwain TJ, Nandi AC, Multiple myeloma treated with high dose intravenous melphalan. Br J Haematol 1987;66:55-62
   PubMed Web of Science ®Google Scholar
• Pritchard J, McElwain TJ, Graham-Pole J. High-dose melphalan with autologous marrow for treatment of advanced neuroblastoma. Br J Cancer 1982;45:86-94
   PubMed Web of Science ®Google Scholar
• Westerfield BT, Michalski JP, McCombs C, Light RW. Reversible melphalan-induced lung damage. Am J Med 1980;68:767-71
   PubMed Web of Science ®Google Scholar
• Olivieri A, Corvatta L, Montanari M, Paroxysmal atrial fibrillation after high-dose melphalan in five patients autotransplanted with blood progenitor cells. Bone Marrow Transplant 1998;21:1049-53
   PubMed Web of Science ®Google Scholar
• Yang J, Terebelo HR, Zonder JA. Secondary primary malignancies in multiple myeloma: an old NEMESIS revisited. Adv Hematol 2012;2012:801495
   PubMedGoogle Scholar
• Blokhin N, Larionov L, Perevodchikova N, Clinical experiences with sarcolysin in neoplastic diseases. Ann NY Acad Sci 1958;68:1128-32
   PubMed Web of Science ®Google Scholar
• McElwain TJ, Powles RL. High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet 1983;2(8354):822-4
   PubMed Web of Science ®Google Scholar
• Barlogie B, Hall R, Zander A, High-dose melphalan with autologous bone marrow transplantation for multiple myeloma. Blood 1986;67:1298-301
   PubMed Web of Science ®Google Scholar
• Giralt S. 200mg/m2 melphalan–the gold standard for multiple myeloma. Nat Rev 2010;7:490-1
   Google Scholar
• Cunningham D, Paz-Ares L, Milan S, High dose Melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma. J Clin Oncol 1994;12:759-63
   PubMed Web of Science ®Google Scholar
• Jagannath S, Vesole DH, Glenn L, Low-risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood stem cell support. Blood 1992;80:1666-72
   PubMed Web of Science ®Google Scholar
• Moreau P, Milpied N, Mahe B, Melphalan 220 mg/m2 followed by peripheral blood stem cell transplantation in 27 patients with advanced multiple myeloma. Bone Marrow Transplant 1999;23:1003-6
   PubMed Web of Science ®Google Scholar
• Philips GL, Meisenberg BR, Reece DE, Activity of single-agent melphalan 220 to 300 mg/m2 with amifostine cytoprotection and autologous hematopoietic stem cell support in non-Hodgkin and Hodgkin lymphoma. Bone Marrow Transplant 2004;10:473-83
   Web of Science ®Google Scholar
• Palumbo A, Bringhen S, Bruno B, Melphalan 200 mg/m(2) versus melphalan 100 mg/m(2) in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study. Blood 2010;115(10):1873-9
   PubMed Web of Science ®Google Scholar
• Kumar SK, Dingli D, Lacy MQ, Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: results from a matched pair analysis. Am J Hematol 2008;83:614-17
   PubMed Web of Science ®Google Scholar
• Badros A, Barlogie B, Siegel E, Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years. Br J Haematol 2001;114:600-7
   PubMed Web of Science ®Google Scholar
• Bashir Q, Shah N, Parmar S, Feasibility of autologous hematopoietic stem cell transplant in patients aged >/=70 years with multiple myeloma. Leuk Lymphoma 2012;53:118-22
   PubMed Web of Science ®Google Scholar
• Badros A, Barlogie B, Siegel E, Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol 2001;114:822-9
   PubMed Web of Science ®Google Scholar
• Raab MS, Breitkreutz I, Hundemer M, The outcome of autologous stem cell transplantation in patients with plasma cell disorders and dialysis-dependent renal failure. Haematologica 2006;91:1555-8
   PubMed Web of Science ®Google Scholar
• Parikh GC, Amjad AI, Saliba RM, Autologous hematopoietic stem cell transplantation may reverse renal failure in patients with multiple myeloma. Biol Blood Marrow Transplant 2009;15:812-16
   PubMed Web of Science ®Google Scholar
• Siegel DS, Desikan KR, Mehta J, Age is not a prognostic variable with autotransplants for multiple myeloma. Blood 1999;93:51-4
   PubMed Web of Science ®Google Scholar
• Palumbo A, Triolo S, Argentino C, Dose-intensive melphalan with stem cell support (MEL100) is superior to standard treatment in elderly myeloma patients. Blood 1999;94:1248-53
   PubMed Web of Science ®Google Scholar
• Palumbo A, Bringhen S, Petrucci MT, Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. Blood 2004;104:3052-7
   PubMed Web of Science ®Google Scholar
• Lenhoff S, Hjorth M, Westin J, Impact of age on survival after intensive therapy for multiple myeloma: a population-based study by the Nordic Myeloma Study Group. Br J Haematol 2006;133:389-96
   PubMed Web of Science ®Google Scholar
• Facon T, Mary JY, Hulin C, Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99–06): a randomized trial. Lancet 2007;370:1209-18
   PubMed Web of Science ®Google Scholar
• Shaw PJ, Nath CE, Nivison-Smith I, Higher melphalan exposure is associated with improved overall survival for myeloma patients undergoing autologous transplant. Biol Blood Marrow Transplant 2012;18:S207
   Web of Science ®Google Scholar
• Barlogie B, Alexanian R, Dicke K, High dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma. Blood 1987;70:869-72
   PubMed Web of Science ®Google Scholar
• Adkins DR, DiPersio JF. Total body irradiation before an allogeneic stem cell transplantation: is there a magic dose? Curr Opin Hematol 2008;15:555-60
   PubMed Web of Science ®Google Scholar
• Zaucha RE, Buckner DC, Barnett T, Modified total body irradiation as a planned second high-dose therapy with stem cell infusion for patients with bone-based malignancies. Int J Radiat Oncol Biol Phys 2006;64:227-34
   PubMed Web of Science ®Google Scholar
• Moreau P, Facon T, Leleu X, Comparison of 200 mg/mq melphalan and 8 Gy total body irradiation plus 140 mg/mq melphalan as conditioning regimen for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the intergroup11 Francophone du Myelome 9502 randomized trial. Blood 2002;99:731-5
   PubMed Web of Science ®Google Scholar
• Goldschmidt H, Hegenbart U, Wallmeier M, High-dose therapy with peripheral blood progenitor cell transplantation in multiple myeloma. Ann Oncol 1997;8:243-6
   PubMed Web of Science ®Google Scholar
• Bjorkstrand B, Svensson H, Goldschmidt H, 5489 autotransplants in multiple myeloma: a registry from the EBMT [abstract]. Blood 1999;94(Suppl 1):714 a
   Google Scholar
• Wong JY, Rosenthal J, Liu A, Image-guided total-marrow irradiation using helical tomotherapy in patients with multiple myeloma and acute leukemia undergoing hematopoietic cell transplantation. Int J Radiat Oncol Biol Phys 2009;73:273-9
   PubMed Web of Science ®Google Scholar
• Schultheiss TE, Wong J, Liu A, Image-guided total marrow and total lymphatic irradiation using helical tomotherapy. Int J Radiat Oncol Biol Phys 2007;67:1259-67
   PubMed Web of Science ®Google Scholar
• Somlo G, Spielberger R, Frankel P, Total marrow irradiation: a new ablative regimen as part of tandem autologous stem cell transplantation for patients with multiple myeloma. Clin Cancer Res 2011;17(1):174-82
   PubMed Web of Science ®Google Scholar
• Galaup A, Paci A. Pharmacology of dimethanesulfonate alkylating agents: busulfan and treosulfan. Expert Opin Drug Metab Toxicol 2012
   PubMed Web of Science ®Google Scholar
• Lahuerta JJ, Grande C, Blade J, Myeloablative treatments for multiple myeloma: update of a comparative study of different regimens used in patients from the Spanish registry for transplantation in multiple myeloma. Leuk Lymphoma 2002;43(1):67-74
   PubMed Web of Science ®Google Scholar
• Lahuerta JJ, Martinez-Lopez J, Grande C, Conditioning regimens in autologous stem cell transplantation for multiple myeloma: a comparative study of efficacy and toxicity from the Spanish Registry for Transplantation in Multiple Myeloma. Br J Haematol 2000;109(1):138-47
   PubMed Web of Science ®Google Scholar
• Carreras E, Rosinol L, Terol MJ, Veno occlusive disease of the liver after high dose cytoreductive therapy with busulfan and melphalan for autologous blood stem cell transplantation in multiple myeloma patients. Biol Blood Marrow Transplant 2007;13(12):1448-54
   PubMed Web of Science ®Google Scholar
• Lahuerta JJ, Mateos MV, Martínez-López J, Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study. Haematologica 2010;95(11):1913-20
   PubMed Web of Science ®Google Scholar
• Ciurea SO, Andersson BS. Busulfan in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2009;15(5):523-36
   PubMed Web of Science ®Google Scholar
• Krivoy N, Hoffer E, Lurie Y, Busulfan use in hematopoietic stem cell transplantation: pharmacology, dose adjustment, safety and efficacy in adults and children. Curr Drug Saf 2008;3(1):60-6
   PubMedGoogle Scholar
• Blanes M, de la Rubia J, Lahuerta JJ, Single daily dose of intravenous busulfan and melphalan as a conditioning regimen for patients with multiple myeloma undergoing autologous stem cell transplantation: a phase II trial. Leuk Lymphoma 2009;50(2):216-22
   PubMed Web of Science ®Google Scholar
• Stadtmauer EA, Ratanatharathorn V, Yeh RF. Final Report of Safety and Efficacy From a Novel Conditioning Regimen, Individualized Once-Daily Intravenous Busulfan with Bortezomib, in Relapsed Multiple Myeloma Patients Undergoing a Second Autologous Hematopoietic Stem Cell Transplantation. ASH; 2012
   Google Scholar
• BuMel Conditioning Regimen for ASCT in Newly Diagnosed Multiple Myeloma Patients + Lenalidomide Maintenance After ASCT (BuMelMCRN001) ClinicalTrials.gov identifier: NCT01702831
   Google Scholar
• Korycka-Wołowiec A, Robak T. Pharmacokinetic evaluation and therapeutic activity of bendamustine in B-cell lymphoid malignancies. Expert Opin Drug Metab Toxicol 2012;8(11):1455-68
   PubMed Web of Science ®Google Scholar
• Leoni LM, Hartley JA. Mechanism of action: the unique pattern of bendamustine-induced cytotoxicity. Semin Hematol 2011;48(Suppl 1):S12-23
   Google Scholar
• Visani G, Malerba L, Stefani PM, BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients. Blood 2011;118(12):3419-25
   PubMed Web of Science ®Google Scholar
• Pönisch W, Bourgeois M, Moll B, Combined bendamustine, prednisone and bortezomib (BPV) in patients with relapsed or refractory multiple myeloma. J Cancer Res Clin Oncol 2013;139(3):499-508
   PubMed Web of Science ®Google Scholar
• Berenson JR, Yellin O, Bessudo A, Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. Br J Haematol 2013;160(3):321-30
   PubMed Web of Science ®Google Scholar
• Conditioning Regimen of Bendamustine and Melphalan Followed by Transplant in Patients With Multiple Myeloma. ClinicalTrials.gov identifier: NCT00916058
   Google Scholar
• Mark TM, Reid W, Niesvizky R, A phase 1 study of bendamustine and melphalan conditioning for autologous stem cell transplant in multiple myeloma. Biol Blood Marrow Transplant 2013; pii: S1083-8791(13)00098-0. doi: 10.1016/j.bbmt.2013.02.013
   Google Scholar
• Adams J, Palombella VJ, Sausville EA, Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999;59(11):2615-22
   PubMed Web of Science ®Google Scholar
• Mitsiades N, Mitsiades C, Richardson P, The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2003;101:2377-80
   PubMed Web of Science ®Google Scholar
• San Miguel JF, Schlag R, Khuageva NK, Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008;359(9):906-17
   PubMed Web of Science ®Google Scholar
• Yarde DN, Oliveira V, Mathews L, Targeting the Fanconi anemia/BRCA pathway circumvents drug resistance in multiple myeloma. Cancer Res 2009;69:9367-75
   PubMedGoogle Scholar
• Nishihori T, Alekshun TJ, Shain K, Bortezomib salvage followed by a Phase I/II study of bortezomib plus high-dose melphalan and tandem autologous transplantation for patients with primary resistant myeloma. Br J Haematol 2012;157(5):553-63
   PubMed Web of Science ®Google Scholar
• Roussel M, Moreau P, Huynh A, Bortezomib ad high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM). Blood 2010;115:32-7
   PubMed Web of Science ®Google Scholar
• Thompson PA, Prince HM, Seymour JF, Bortezomib added to high-dose melphalan as pre-transplant conditioning is safe in patients with heavily pretreated multiple myeloma. Bone Marrow Transplant 2011;46:764-5
   PubMed Web of Science ®Google Scholar
• Lee SR, Kim SJ, Park Y. Bortezomib and melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma. Korean J Hematol 2010;45(3):183-7
   PubMedGoogle Scholar
• Lonial S, Kaufman J, Tighiouart M, A phase I/II trial combining high-dose melphalan and autologous transplant with bortezomib for multiple myeloma: a dose and schedule finding study. Clin Cancer Res 2010;16:5079-86
   PubMed Web of Science ®Google Scholar
• Wong Doo N, Thompson P, Prince H, Bortezomib with high dose melphalan conditioning for autologous transplantation is safe and effective in patients with heavily pre-treated and high risk multiple myeloma. Leuk Lymphoma 2012; Epub ahead of print
   Web of Science ®Google Scholar
• Huang W, Li J, Li H, High-dose melphalan with bortezomib as conditioning regimen for autologous stem cell transplant in patients with newly diagnosed multiple myeloma who exhibited at least very good partial response to bortezomib-based induction therapy. Leuk Lymphoma 2012;53(12):2507-10
   PubMed Web of Science ®Google Scholar
• Kim JS, Min CK, Yoon SS, A phase 1/2, open-label, prospective, multicenter study to evaluate the efficacy and safety of the lower dose of bortezomib plus busulfan and melphalan as a conditioning regimen in patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation: result of phase 1 trial. Blood (ASH Annual Meeting Abstracts) 2012. 120: 1937
   Google Scholar
• McCormack PL. Carfilzomib: in relapsed, or relapsed and refractory, multiple myeloma. Drugs 2012;72(15):2023-32
   PubMed Web of Science ®Google Scholar
• Carfilzomib + High Dose Melphalan as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation ClinicalTrials.gov identifier: NCT01690143
   Google Scholar
• Berenson JR, Boccia R, Siegel D, Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single-arm study. Br J Haematol 2006;135:174-83
   PubMed Web of Science ®Google Scholar
• Qazilbash MH, Saliba RM, Nieto Y, Arsenic trioxide with ascorbic acid and high dose melphalan: results of a phase II randomized trial. Biol Blood Marrow Transplant 2008;14:1401-7
   PubMed Web of Science ®Google Scholar
• Sharma M, Khan H, Thall PF, A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid. Cancer 2012;118(9):2507-15
   PubMed Web of Science ®Google Scholar
• Giralt S, Bensinger W, Goodman M, 166Ho DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: results of two phase 1/2 trials. Blood 2003;102(7):2684-91
   PubMed Web of Science ®Google Scholar
• Christoforidou AV, Saliba RM, Williams P, Results of a retrospective single institution analysis of targeted skeletal radiotherapy with (166)Holmium-DOTMP as conditioning regimen for autologous stem cell transplant for patients with multiple myeloma. Impact on transplant outcomes. Biol Blood Marrow Transplant 2007;13(5):543-9
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Wiseman GA, Lacy MQ, A phase II study of (153) Sm-EDTMP and high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma. Am J Hematol 2010;85:409-13
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Gertz MA, Lacy MQ, A phase I trial of zevalin radioimmunotherapy with high-dose melphalan (HDM) and autologous stem cell transplant (ASCT) for multiple myeloma (MM). Blood (ASH Annual Meeting Abstracts) 2011;118:3095
   Google Scholar
• Paíno T, Ocio EM, Paiva B, CD20 positive cells are undetectable in the majority of multiple myeloma cell lines and are not associated with a cancer stem cell phenotype. Haematologica 2012;97(7):1110-14
   PubMed Web of Science ®Google Scholar